DALLAS, March 3, 2021 /PRNewswire/ -- Lantern
Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical
company using its proprietary RADR® artificial
intelligence ("A.I.") platform to improve cancer drug discovery and
development, and identify patients who will benefit from its
portfolio of targeted oncology therapeutics, announced today that
it will host a conference call and live webcast on Wednesday, March 10, 2021 at 4:00 p.m. ET to discuss financial and operating
results for the fourth quarter and fiscal year ended December 31, 2020.
The call will be led by Panna
Sharma, President and Chief Executive Officer. He will be
joined on the call by other members of the management team.
Interested participants and investors may access the conference
call via teleconference or online.
Conference Call & Webcast
Details
Toll-free Domestic & Canada: 877.830.2592 conference ID:
61024
International: 785.424.1739 – conference ID 61024
US and Canada callers one touch
dial: +1. 877.830.2592,, 61024#
Live audio-only webcast and related presentation materials will
also be accessible at:
https://www.webcaster4.com/Webcast/Page/2460/40269. Web
participants should register 15 minutes prior to the start of the
call. The webcast will be archived on the Lantern Pharma website
for 45 days.
Replay Details
A replay
of the conference call will be available through 11:59 p.m. ET on April 10,
2021.
Replay Toll-free Domestic & Canada: 1.800.938.2795 – passcode:
61024
Replay International: 1.402.220.9029 – passcode:
61024
About Lantern Pharma
Lantern Pharma (LTRN) is a
clinical-stage biopharmaceutical company innovating the
revitalization, refocusing and development of precision
therapeutics in oncology. We leverage advances in machine learning,
genomics, and artificial intelligence by using our proprietary A.I.
platform to discover biomarker signatures that help identify
patients more likely to respond to our pipeline of cancer
therapeutics. Lantern's focus is to improve the outcome for
patients by leveraging our technology to uncover, rescue and
develop abandoned or failed drugs. Our current pipeline of three
drugs, with two programs in clinical stages and two in preclinical,
focuses on cancers that have unique and unmet clinical needs with a
clearly defined patient population. We believe that the use of
machine learning, genomics and computational methods can help
accelerate the revitalization, refocusing and development of small
molecule-based therapies. By targeting drugs to patients whose
genomic profile identifies them as having the highest probability
of benefiting from the drug, this approach represents the potential
to deliver best-in-class outcomes. Our team seeks out experienced
industry partners, world-class scientific advisors, and innovative
clinical-regulatory approaches to assist in delivering cancer
therapies to patients as quickly and efficiently as possible. For
more information, please visit the company's website at
www.lanternpharma.com or follow the company on Twitter
@lanternpharma.
Contact
Marek
Ciszewski, JD
Director, Investor Relations
628-777-3167
IR@lanternpharma.com
Forward-looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements include, among other things, statements relating to:
future events or our future financial performance; the potential
advantages of our RADR® platform in identifying drug
candidates and patient populations that are likely to respond to a
drug candidate; our strategic plans to advance the development of
our drug candidates and antibody drug conjugate (ADC) development
program; estimates regarding the development timing for our drug
candidates and ADC development program; our research and
development efforts of our internal drug discovery programs and the
utilization of our RADR® platform to streamline the drug
development process; our intention to leverage artificial
intelligence, machine learning and genomic data to streamline and
transform the pace, risk and cost of oncology drug discovery and
development and to identify patient populations that would likely
respond to a drug candidate; estimates regarding potential markets
and potential market sizes; sales estimates for our drug candidates
and our plans to discover and develop drug candidates and to
maximize their commercial potential by advancing such drug
candidates ourselves or in collaboration with others. Any
statements that are not statements of historical fact (including,
without limitation, statements that use words such as "anticipate,"
"believe," "contemplate," "could," "estimate," "expect," "intend,"
"seek," "may," "might," "plan," "potential," "predict," "project,"
"target," "aim," "should," "will," "would," or the negative of
these words or other similar expressions) should be considered
forward-looking statements. There are a number of important factors
that could cause our actual results to differ materially from those
indicated by the forward-looking statements, such as (i) the impact
of the COVID-19 pandemic, (ii) the risk that we may not be able to
successfully initiate, conduct, or conclude clinical testing for or
obtain marketing approval for our product candidates; (iii) the
risk that no drug product based on our proprietary RADR A.I.
platform has received FDA marketing approval or otherwise been
incorporated into a commercial product, and (iv) those other
factors set forth in the Risk Factors section in our final
prospectus, dated January 14, 2021,
for our follow-on public offering, on file with the Securities and
Exchange Commission. You may access our January 14, 2021 final prospectus under the
investor SEC filings tab of our website at
www.lanternpharma.com or on the SEC's website at www.sec.gov.
Given these risks and uncertainties, we can give no assurances that
our forward-looking statements will prove to be accurate, or that
any other results or events projected or contemplated by our
forward-looking statements will in fact occur, and we caution
investors not to place undue reliance on these statements. All
forward-looking statements in this press release represent our
judgment as of the date hereof, and, except as otherwise required
by law, we disclaim any obligation to update any forward-looking
statements to conform the statement to actual results or changes in
our expectations.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-to-host-fourth-quarter-and-fiscal-year-end-2020-operating-and-financial-results-conference-call-on-march-10-2021-at-400-pm-et-301239392.html
SOURCE Lantern Pharma